Lv31
350 积分 2023-04-28 加入
Bayesian efficient safety monitoring: a simple and well-performing framework to continuous safety monitoring of adverse events in randomized clinical trials
2小时前
待确认
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2个月前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
3个月前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
4个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
4个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
5个月前
已完结
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
5个月前
已完结
Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
5个月前
已完结
The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?
5个月前
已完结
Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
6个月前
已完结
皖公网安备34019202002308
